Down-Regulation of Nitric Oxide Synthase May Account for the Antiinflammatory Activities of Copper Chelates

  • John R. J. Sorenson


Roles of nitric oxide (·N=O, NO) in decreasing vascular tone, decreasing platelet adhesion and aggregation, increasing the cytotoxic response of macrophages and neutrophils, and serving as a retrograde neurotransmitter in normal biochemically-mediated physiological responses have been reviewed by Moncada, Palmer, and Higgs (1), Lancaster (2). These reviews also present pathological consequences of excess synthesis of NO by Nitric Oxide Synthase (NOS) which include: pain, inflammations, gastrointestinal ulcers, seizures, neoplasias, diabetes, ischemia-reperfusion injuries, and radiation injuries. Synthesis of NO involves an NADPH-dependent diaphorase which supplies reducing equivalents for the conversion L-Arginine to NO.


Copper Complex Isosorbide Dinitrate Rheumatoid Arthritic Morphine Dependence Rheumatoid Arthritic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Moncada, R. M. J. Palmer and E. A. Higgs, Pharmacol. Rev. 43, 109–142 (1991).Google Scholar
  2. 2.
    J. R. Lancaster Jr., Am. Scient. 80, 248–259 (1992).Google Scholar
  3. 3.
    U. Weser, C. Richter, A. Wendel and M. Younes, Bioinorg. Chem. 8, 201–213 (1978).CrossRefGoogle Scholar
  4. 4.
    C. Richter, A. Azzi, U. Weser and A. Wendel, J. Biol. Chem. 252, 5061–5066 (1977).Google Scholar
  5. 5.
    J. Werringloer, S. Kowano, N. Chacos, and R. W. Estabrook, J. Biol. Chem. 254, 11839–11846 (1979).Google Scholar
  6. 6.
    J.J. Reiners, Jr., E. Brott and J. R. J. Sorenson, Carcinogenesis 7, 1729–1732 (1986).CrossRefGoogle Scholar
  7. 7.
    R. D. Skinner, C. Conrad, V. Henderson, S. A. Gilmore and E. Garcia-Rill, Exptl. Neurol 104, 15–21 (1989).CrossRefGoogle Scholar
  8. 8.
    J. R. J. Sorenson, Prog. Med. Chem. 26, 437–568 (1989).CrossRefGoogle Scholar
  9. 9.
    J.R.J. Sorenson, L.S.F. Soderberg, L.W. Chang, W.M. Willingham, M.L. Baker, J.B. Barnett, H. Salari and K. Bond, Eur. J. Med. Chem. 28, 221–229 (1993).CrossRefGoogle Scholar
  10. 10.
    J.G.L. Baquial and J.R.J. Sorenson, J. Inorg. Biochem. 60, 133–148 (1995).CrossRefGoogle Scholar
  11. 11.
    U. Weser, C. Richter, A. Wendel and M. Younes, Bioinorg. Chem. 8, 201–213 (1978).CrossRefGoogle Scholar
  12. 12.
    G. A. Reed and C. Madhu, in Biology of Copper Complexes, J.R.J. Sorenson, ed., Humana Press, Totowa, N.J., pp. 287–298 (1987).CrossRefGoogle Scholar
  13. 13.
    S. Pou, W. S. Pou, D. S. Bredt, S. H. Snyderand G. M. Rosen, J. Biol. Chem. 267, 24173–24176 (1992).Google Scholar
  14. 14.
    N. McCartney-Francis, J. B. Allen, D. E. Mizel, J. E. Albina, Q. Xie, C. F. Nathan, and S.M. Wahl, J. Exptl. Med. 178, 749–754 (1993).CrossRefGoogle Scholar
  15. 15.
    H. Najafipour and W. R. Ferrell, Exptl. Physiol. 78, 615–624 (1993).Google Scholar
  16. 16.
    A. Ialenti, S. Moncada and M. DiRosa, Br. J. Pharmacol. 110, 701–706 (1993).CrossRefGoogle Scholar
  17. 17.
    M. J. S. Miller, S. Chotinaruemol, H. Sadowska-Krowicka, J.L. Kakkis, U. K. Munshi, X.-J. Zhang and D. A. Clark, Agents Actions 39, C180–C182 (1993).CrossRefGoogle Scholar
  18. 18.
    S. Hortelano, A. M. Genaro and L. Bosca, FEBS 320, 135–139 (1993).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • John R. J. Sorenson
    • 1
  1. 1.Department of Medicinal Chemistry, College of PharmacyUniversity of Arkansas for Medical Sciences CampusLittle RockUSA

Personalised recommendations